Sunday 18 October 2026
Export PRLD’s income statement to Excel — free account
Prelude Therapeutics Incorporated
PRLD Healthcare Biotechnology
Prelude Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.1 million, up 73.4% from fiscal 2024. In the quarter to June 2026, revenue grew 42.6%, EPS grew 65.9% and free cash flow grew 40.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.26
0.06
−1.81%
Follow PRLD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 11.66 | 13.62 | 23.39 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.74) | 9.65 | (13.01) | (33.67) | |
P/B ratio |
1.87 | 3.25 | 4.69 | 3.92 | |
Price to Tangible BV |
1.87 | 3.25 | 4.69 | 3.92 | |
EV/Sales |
0.00 | 6.27 | 9.68 | 16.62 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.55) | (2.13) | (4.59) | (11.21) | |
EV/FCF |
(0.55) | (2.13) | (4.58) | (11.18) | |
Quick Ratio |
3.02 | 1.95 | 1.95 | 3.99 | |
Current Ratio |
3.21 | 1.99 | 2.03 | 4.07 | |
Net Debt/EBITDA |
2.74 | 6.03 | 5.75 | 9.85 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.12 | 0.16 | 0.15 | |
Operating CF/Net income |
0.97 | (1.40) | 2.09 | 1.12 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
333.97% | 319.01% | 296.97% | 282.80% | |
Selling, General and Administrative Expense of Revenue |
80.15% | 88.58% | 112.58% | 88.13% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
37.28% | 32.70% | 43.67% | 35.54% | |
Graham Net Nets |
0.20 | 0.15 | 0.09 | 0.19 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(102.08%) | (44.48%) | (29.24%) | (13.70%) | |
Free Cash Flow Yield |
(91.48%) | (25.26%) | (15.53%) | (6.35%) | |
Revenue per Share |
0.09 | 0.07 | 0.06 | 0.06 | |
Operating CF per Share |
(0.25) | 0.30 | (0.26) | (0.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.25) | 0.30 | (0.26) | (0.16) | |
Cash per Share |
0.72 | 1.34 | 0.99 | 1.54 | |
Shareholders Equity per Share |
0.77 | 0.89 | 0.73 | 1.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.77 | 0.89 | 0.73 | 1.36 | |
Free Cash Flow |
(19.11) | 23.12 | (21.68) | (15.57) | |
Working Capital |
40.14 | 52.70 | 42.87 | 116.86 | |
Capital Expenditures |
0.00 | 0.00 | — | — | |
Net Current Asset Value |
22.11 | 33.01 | 25.13 | 99.27 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
4.23 | 5.86 | 3.95 | 3.50 | |
Average Assets |
145.99 | 158.42 | 130.45 | 152.14 | |
Average Common Equity |
107.48 | 100.05 | 81.68 | 104.79 |
Columns are period end dates